SRR1797282
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 47
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.440
- E2F_TARGETS+0.310
- MITOTIC_SPINDLE+0.280
- G2M_CHECKPOINT+0.270
- MYC_TARGETS_V1+0.270
- DNA_REPAIR+0.260
- OXIDATIVE_PHOSPHORYLATION+0.260
- INTERFERON_ALPHA_RESPONSE+0.250
- INTERFERON_GAMMA_RESPONSE+0.200
- PANCREAS_BETA_CELLS+0.200
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.480
- ANGIOGENESIS-0.420
- TNFA_SIGNALING_VIA_NFKB-0.350
- NOTCH_SIGNALING-0.340
- KRAS_SIGNALING_DN-0.320
- APICAL_JUNCTION-0.290
- MYOGENESIS-0.290
- ESTROGEN_RESPONSE_EARLY-0.270
- APICAL_SURFACE-0.260
- COAGULATION-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R137 | — | — | 0.903 |
| 2 | R135 | — | — | 0.893 |
| 3 | 004589d9-7eb6-46cb-b822-20cd1939aa7e | — | — | 0.880 |
| 4 | SRR1797275 | — | cohortSC | 0.876 |
| 5 | R144 | — | — | 0.852 |
| 6 | R391 | — | — | 0.850 |
| 7 | d01f4531-b145-414b-bc1c-0f1a148b771e | — | — | 0.842 |
| 8 | SRR11296733 | — | — | 0.838 |
| 9 | SRR1797281 | — | cohortSC | 0.838 |
| 10 | MNG386 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |